

Journal of Diabetes and Endocrinology

Volume 4 Number 4 September 2013

ISSN 2141-2685



*Academic
Journals*

ABOUT JDE

The **Journal of Diabetes and Endocrinology (JDE)** is published monthly (one volume per year) by Academic Journals.

Journal of Diabetes and Endocrinology (JDE) is an open access journal that provides rapid publication (monthly) of articles in all areas of the subject such as steroid hormones, clinical chemistry and biochemistry, neuroendocrinology, hypoglycemia in diabetes etc.

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in JDE are peer-reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: jde@academicjournals.org. A manuscript number will be mailed to the corresponding author shortly after submission.

The Journal of Diabetes and Endocrinology will only accept manuscripts submitted as e-mail attachments.

Please read the **Instructions for Authors** before submitting your manuscript. The manuscript files should be given the last name of the first author.

Editors

Prof. Masayoshi Yamaguchi

*Division of Endocrinology and Metabolism and Lipids,
Department of Medicine,
Emory University School of Medicine,
1639 Pierce Drive, 1305 WMRB, Atlanta,
Georgia 30322-0001,
USA.*

Dr. Krishna M. Boini

*Department of Pharmacology and Toxicology,
Virginia Commonwealth University,
1220 East Broad Street, MSB II, Room # 3054
Richmond, VA - 23298.
USA*

Dr. Mohamed A. M. Mohamed Dkhil Hamad

*Zoology Dept. College of Science,
King Saud University,
Egypt.*

Dr. Aliyu Mohammed

*Department of Human Physiology
Ahmadu Bello University, Zaria.
Nigeria*

Prof. Bhupen Chandra Behera

*Gayatri College of Pharmacy,
Gayatri Vihar, Jamadarpali,
Sambalpur- 768200, Orissa
India.*

Dr. Srinivas Nammi

*Research Academic
Faculty of Pharmacy
The University of Sydney
NSW 2006,
Australia.*

Dr. Mamdouh Moawad Ali Hassan

*Biochemistry Department
Genetic Engineering & Biotechnology Division
National Research Center
El Tahrir St., El Dokki 12622
Cairo,
Egypt.*

Editorial Board

Dr. Fawad Javed

*Karolinska Institutet,
Department of Dental Medicine,
Huddinge,
Sweden*

Prof. Hab Lidia Rudnicka

*Dept. Dermatology,
Central Clinical Hospital,
MSWiA, Warsaw,
Poland*

Dr. Aamir (Amer) Jalal Al Mosawi

*University of Baghdad
College of Medicine
Iraq*

Dr. Abbasi

*Tehran University of Medical Sciences,
Tehran,
Iran*

Dr. Rehab Fawzy Abdel-Rahman

*Department of Pharmacology,
National Research Centre (NRC),
El- Tahrir St. Dokki, Cairo,
Egypt.*

Dr. JIMOH, Ahmed Kayode

*Titilayo Street, Isale Afo,
Ikirun Ifelodun LGA
Kwara State
Nigeria*

Dr. Saganuwan Alhaji Saganuwan

*Department of Veterinary Physiology,
Pharmacology & Biochemistry,
University of Agriculture Benue State,
Nigeria.*

Dr. Alireza Shirpoor

*Permanent lecturer of
Urmia University of Medical Sciences
Iran*

Dr. Bassim Atta

*Prof. Food Chemistry & Analysis
Faculty of Agriculture
Tanta University
Egypt*

Prof. (Dr.) Bhupen Chandra Behera

*Gayatri College of Pharmacy,
Gayatri Vihar, Jamadarpali,
Sambalpur- 768200, Orissa
India*

Dr. Ben-zhi Cai

*Baojian Road 157#, Harbin,
150081,
China.*

Dr. Chatchalit Rattarasarn

*Division of Endocrinology and Metabolism
Department of Medicine
Ramathibodi hospital, Mahidol university
Bangkok,
Thailand 10400*

Dr. Sónia Catarina Correia

*Centre for Neuroscience and Cell Biology,
Department of Zoology,
University of Coimbra,
3004-517 Coimbra
Portugal*

Mohamed A. M. M. Dkhil Hamad

*faculty of science,
Helwan University,
Egypt.*

Dr. Bakari Adamu Girei

*Department of Medicine,
Ahmadu Bello University
Zaria,
Nigeria*

Dr. Aliyu Mohammed

*Adamawa State,
Nigeria*

Ana Isabel Marques Duarte

*Center for Neuroscience & Cell Biology
Institute of Biochemistry, Faculty of Medicine (Pólo I)
University of Coimbra
3004-504 Coimbra
Portugal*

Instructions for Author

Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The **cover letter** should include the corresponding author's full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author's surname, as an attachment.

Article Types

Three types of manuscripts may be submitted:

Regular articles: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

Reviews: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

Review Process

All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers' comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the JDE to publish manuscripts within weeks after submission.

Regular articles

All portions of the manuscript must be typed double-spaced and all pages numbered starting from the title page.

The Title should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 key words that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The Introduction should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Materials and methods should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail.

Results should be presented with clarity and precision.

The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The Discussion should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The Acknowledgments of people, grants, funds, etc should be brief.

Tables should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of in the text. The same data should not be presented in both table and graph form or repeated in the text.

Figure legends should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

References: In the text, a reference identified by means of an author's name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author's name should be mentioned, followed by 'et al'. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like 'a' and 'b' after the date to distinguish the works.

Examples:

Abayomi (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 1992), (Chege, 1998;

1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001)

References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:

Chikere CB, Omoni VT and Chikere BO (2008). Distribution of potential nosocomial pathogens in a hospital environment. *Afr. J. Biotechnol.* 7: 3535-3539.

Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005). Methicillinresistant *Staphylococcus aureus* in community-acquired skin infections. *Emerg. Infect. Dis.* 11: 928-930.

Pitout JDD, Church DL, Gregson DB, Chow BL, McCracken M, Mulvey M, Laupland KB (2007). Molecular epidemiology of CTXM-producing *Escherichia coli* in the Calgary Health Region: emergence of CTX-M-15-producing isolates. *Antimicrob. Agents Chemother.* 51: 1281-1286.

Pelczar JR, Harley JP, Klein DA (1993). *Microbiology: Concepts and Applications.* McGraw-Hill Inc., New York, pp. 591-603.

Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage.

Fees and Charges: Authors are required to pay a \$550 handling fee. Publication of an article in the Journal of Diabetes and Endocrinology is not contingent upon the author's ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances.

Copyright: © 2013, Academic Journals.

All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

Disclaimer of Warranties

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the JDE, whether or not advised of the possibility of damage, and on any theory of liability.

This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication. While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.

Journal of Diabetes and Endocrinology

Table of Content: Volume 4 Number 4 September 2013

ARTICLES

Research Articles

- Hepatoprotective and anti-diabetic effect of combined extracts of *Moringa oleifera* and *Vernonia amygdalina* in streptozotocin-induced diabetic albino Wistar rats** 45
Efiong E. E., Igile G. O., Mgbeje B. I. A., Otu E. A. and Ebong P. E
- Comparison between the clinical efficacy of linagliptin and sitagliptin** 51
Naoto Kamatani, Taiya Katoh, Yoshikuni Sawai, Hitoshi Kanayama, Naoyuki Katada and Mitsuyasu Itoh

Full Length Research Paper

Hepatoprotective and anti-diabetic effect of combined extracts of *Moringa oleifera* and *Vernonia amygdalina* in streptozotocin-induced diabetic albino Wistar rats

Efiong E. E., Igile G. O.*, Mgbeje B. I. A., Otu E. A. and Ebong P. E.

Department of Biochemistry, Faculty of Basic Medical Sciences, University of Calabar, P. M. B. 1115, Calabar, Nigeria.

Accepted 10 September, 2013

This study was carried out to investigate the hepato-protective properties of combined extracts of *Moringa oleifera* (MO) and *Vernonia amygdalina* (VA) in streptozotocin (STZ) induced diabetic albino Wistar rats. The study design involved 42 rats weighing 120 to 180 g which were divided into 7 groups of 6 rats each. Groups 1 and 2 representing normal and diabetic control (NC and DC) received 0.5 ml of dimethylsulphoxide (DMSO). Group 3 received 5 IU/kg body weight insulin intraperitoneally and group 4 received 5 mg/kg body weight glibenclamide (GB) orally; groups 5 and 6 received 500 mg/kg body weight of MO and VA, respectively while group 7 the combined treatment group received 250 mg/kg body weight of each extract. After 28 days of treatment, the animals were anaesthetized and sacrificed to obtain blood by cardiac puncture. Serum was collected and assayed for alanine aminotransaminase (ALT), aspartate aminotransferases (AST) and alkaline phosphatase (ALP), total protein (TP) and albumin. The results showed that ALT, AST and ALP levels of the treatment groups decreased significantly ($P < 0.05$) when compared with NC and DC, but were higher than reference drugs. The combined extract significantly ($P < 0.05$) decreased the blood glucose sugar level, and this action compared favourably with the results obtained with the standard drugs. There was a significant increase ($P < 0.05$) in TP and albumin levels of the treatment groups when compared with DC. Fasting blood glucose (FBG) showed significant decrease ($P < 0.05$) in all treated groups compared to NC and DC. Moreover, the body weight change for the treatment groups showed a progressive decrease ($P < 0.05$) except for groups treated with VA and MO when compared with NC. The results thus, show that single and combined extracts of MO and VA has hepatoprotective effects and may be safer in preventing diabetes induced damage to the liver.

Key words: Diabetes mellitus, liver enzymes, lipid profile, hepatoprotective, *Moringa oleifera*, *Vernonia amygdalina*.

INTRODUCTION

Diabetes mellitus is a metabolic disorder of the endocrine system that precipitates disturbances in glucose, lipid and protein homeostasis (Van den Berghe et al., 2006). The disease is found in all parts of the world and it is increasing rapidly worldwide. It is secondary to a deficiency of the number of pancreatic β -cells of the islets of Langerhans or resistance of tissue cells to insulin (Kelly and Fabtus, 1995;

Lang et al., 2005). People suffering from diabetes cannot produce or properly use insulin, and so they persistently have high blood glucose. Diabetes is generally characterized by hyperglycaemia, glucosuria, polyuria, body weight loss, disability, coma and even death (Cockram et al., 1993). Type 2 diabetes is a non-insulin dependent diabetes mellitus, in which the body does not produce enough insulin

*Corresponding author. E-mail: goitech2000@yahoo.com.

or properly use it. It is the most common form of the disease, accounting for over 90% of the cases. Type 2 is nearing epidemic proportion as a result of an increased number of elderly people in the world, some of who are sarcopenic, and a greater prevalence of obesity and sedentary lifestyle. The cause of diabetes is a mystery, although both genetic and environmental factors such as lifestyle, obesity and lack of exercise appear to play a role (Jung et al., 2006). According to the World Health Organization (WHO) projection, the prevalence of diabetes is likely to increase by 35% by the year 2020. Currently, there are over 150 million diabetic patients world-wide and this is likely to increase to over 300 million by the year 2025. Statistical projection on India suggests that the number of diabetics will rise from 15 million in 1995 to 57 million in the year 2025 making it as the country with the highest number of diabetics in the world (Tende et al., 2011). The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million by 2030 (Saxena and Kishore, 2004).

Plants are well known in traditional medicine for their hypoglycaemic effects and available literature indicates that there are more than 800 plant species showing hypoglycaemic activities *in vivo* (Maton et al., 1993). The maximum therapeutic and minimum side effects of herbal remedies have been verified in numerous scientific investigations. Presently, plant materials play major roles in primary health care as therapeutic remedies in many developing countries (Gagliano et al., 2007). This is the reason for which plant materials are continuously being scrutinized and investigated for their potential use as hypoglycaemic agents. Consequently, it has become imperative to investigate plants such as *Moringa oleifera* and *Vernonia amygdalina* which have been used by native populations as hypoglycaemic agents in a standardized experimentation. A number of investigations have shown that saponins, flavonoids and a host of other secondary plant metabolites including arginine and glutamic acid possess hypoglycemic effect in various animal models (Saxena and Kishore, 2004) and have been found to be hepatoprotective in diabetic animal experiments.

Currently, available therapies for diabetes include insulin and various oral antidiabetic agents such as sulfonylurea, biguanides, α -glucosidase inhibitors, and glinides, which are used as monotherapies or in combination to achieve better glycemic regulation. Many of these oral antidiabetic agents have a number of serious adverse effects; thus, managing diabetes without any side effects is still a challenge (Wild et al., 2004). The liver is a vital organ in humans, which has a wide range of functions including detoxification of foreign substances in the body and protein synthesis. Other functions of the liver includes, building complex molecules from simple substances absorbed from the digestive tract, neutralization of toxins, manufacture

of bile which aids fat digestion and removal of toxins through the bowels (Maton et al., 1993). However, the ability of the liver to perform these functions is often inhibited by numerous substances which the human body is exposed to on daily basis. These substances include drugs, medicines, alcohol and tobacco products all of which are injurious to the body and its organs (Gagliano et al., 2007). In the absence of reliable liver-protective drugs in medical practice, herbs have become reliable substitutes and have so far played significant role in the management of various liver disorders and the accompanying oxidative stress.

MATERIALS AND METHODS

Collection of plants

800 g of fresh leaves were harvested from the endocrine research farm of the University of Calabar, Nigeria.

Chemicals and reagents

All chemicals and reagents used in this study were obtained commercially and were all of analytical grade.

Preparation of extract

500 g each of the fresh leaves of *M. oleifera* and *V. amygdalina* were washed in clean water then macerated in 500 ml each of 80% ethanol and was each allowed to stand at room temperature for 48 h. The filtrates were evaporated in a rotary evaporator and allowed to concentrate on a water bath at 36°C. A greenish paste was obtained for each extract. The leaf extracts obtained were stored at <4°C until used.

Experimental animals

Forty two rats of the albino Wistar strain, weighing between 120 and 180 g, were obtained from the animal house of the Department of Biochemistry, University of Calabar, Nigeria. They were divided into 7 groups of 6 rats each and allowed to acclimatize for 7 days at room temperature (26±2°C), relative humidity (45 to 55%) and 12 hrs dark/light cycle. All the animals were fed with standard rat chow and water was allowed *ad libitum* under strict hygienic conditions.

Induction of diabetes

Streptozotocin (STZ) was prepared in citrate buffer (0.1 M, pH 4.5). 0.50 ml of the solution obtained was injected into each animal intraperitoneally at a concentration of 40 mg/kg body weight of rat. Type 1 diabetes was confirmed in fasting rats by determining the blood glucose levels after 72 h post diabetes induction. If the value obtained is more than 150 mg/100 ml, then diabetes has been successfully induced.

Experimental design

Forty two adult albino Wistar rats of both sexes, weighing 120 to

Table 1. Serum enzymes concentrations in treatment groups.

Group	AST	ALT	ALP
NC	58.44±20.34	13.11±4.21	7.12±2.61
DC	175.26±12.53 ^{*,a}	102.55±32.95 [*]	12.61±0.18
INS	11.21±0.92 ^a	10.76±3.53 ^a	5.02±2.55
GB	14.81±7.09 ^a	7.64±2.56 ^a	5.84±0.67
VA	112.12±26.35 ^b	56.15±23.19 ^a	4.54±0.88
MO	62.19±24.64 ^a	8.88±3.70 ^a	7.89±1.55
MO+VA	45.93±14.10 ^a	19.14±3.98 ^a	5.48±3.19

^{*}Significantly different from normal control (NC) at P<0.05.

^aSignificantly different from diabetic control (DC) at P<0.05.

^bSignificantly different from glibenclamide (GB) at P<0.05.

^dSignificantly different from *Vernonia amygdalina* (VA) at P<0.05.

Values are Mean±SEM and n=3 determinations. INS: insulin.

Table 2. Serum proteins concentrations in treatment groups.

Group	Total proteins	Albumin	Globulin
NC	5.99±0.61	4.55±0.31	1.44±0.53
DC	3.14±0.09	2.34±0.14	0.81±0.24
INS	3.76±0.69 ^{*,a}	2.80±0.51 ^{*,a}	0.96±0.20 ^{*,a}
GB	3.25±0.12 ^{*,a,b}	2.49±0.05 ^{*,b}	0.76±0.16 ^{*,b}
VA	4.82±0.93 ^{*,a,b}	3.75±0.65 ^{*,a,b}	0.89±0.28 ^{*,a,b}
MO	3.92±0.07 ^{*,a}	2.35±0.03 [*]	1.58±0.04 ^a
MV	5.23±0.10	4.46±0.10	0.77±0.20

Values are Mean± SEM and n=3 determinations. NC: Normal control; DC: diabetic control; GB: glibenclamide, MO: *Moringa oleifera*; VA: *Vernonia amygdalina*; INS: insulin.

180 g were grouped into 7 groups of 6 rats each as follows: Group 1 served as the normal control (NC) group and were administered 0.5 ml dimethylsulphoxide (DMSO) orally; Group 2 was the diabetic control (DC) group and were administered 0.5 ml DMSO orally; Group 3 received 5 UI/kg body weight insulin (standard drug) intraperitoneally; Group 4 received 5 mg/kg body weight glibenclamide (GB, standard drug) orally; Group 5 received 500 mg/kg body weight of *M. oleifera* (MO) extract; Group 6 received 500 mg/kg body weight of *V. amygdalina* (VA) extract; Group 7 received 250 mg/kg body weight MO + 250 mg/kg body weight VA extracts.

Treatment was administered twice daily (12 hourly) for 28 days.

Statistical analysis

Data obtained from this study were analysed by descriptive statistics and presented as mean ± standard error of mean of three determinations (mean ± SEM), using the statistical software package SPSS for windows version 11.0 (SPSS Inc. Chicago IL). Differences between means were separated using the analysis of variance (ANOVA) and multiple comparison tests. Values of P<0.05 were taken as being significant. Blood glucose levels were expressed in mg/dl as mean ± SEM.

RESULTS

Effects of treatment on liver enzyme markers

The activities of the three most prominent liver enzyme markers, alkaline phosphatase (ALP), alanine amino-transaminase (ALT), and aspartate aminotransaminase (AST) after treatment with plant extracts and standard drugs are shown in Table 1. The serum concentrations of the three liver marker enzymes reduced significantly (P<0.05) for all treatment groups when compared with the DC group. The combined extract treatment was more effective in reversing the enzyme activities when compared with the individual extract treatments. VA treated group significantly (P<0.05) reduced the activity of ALP (4.54±0.88 mg/dl), while the MO treated group was effective on AST (62.19±24.64 mg/dl), ALT (8.88±3.70 mg/dl) and ALP (7.89±1.55 mg/dl), respectively and compared well with the results obtained with the standard drugs.

Effects of treatment on total protein

Table 2 as well as Figure 1 showed the effect of treatments on total protein, albumin and globulin concentrations. Total serum protein for all treatment groups increased significantly (P<0.05) when compared with the DC group. The increase was observed with the results obtained with the standard drugs. The combined treatment group gave a more significant (P<0.05) increase in total protein albumin concentrations when compared with the single extract administered groups.

Effects of treatment on body weight

There was an initial reduction in body weights of experimental groups followed by a sudden gain in weights and the trend was the same with results obtained from the insulin, standard hypoglycemic drug (glibenclamide) and the combined extract treated groups (Table 3).

Effects of treatment on fasting blood glucose level

After the 28 days treatment, there was a significant (P<0.05) reduction in fasting blood glucose levels for the groups treated with plant extracts and the standard drug. The reduction was comparable with that obtained with the standard hypoglycaemic drug (glibenclamide) (Figure 1).

DISCUSSION

Type 1 diabetes was induced in albino Wistar rats using

Table 3. Change in body weights of the different experimental groups.

Group	Body weight (g)					
	Initial weight	Day 6	Day 12	Day 18	Day 24	Day 30
NC	107.86±4.35	124.57±2.35	124.66±2.83	131.23±2.14	138.13±2.09	139.53±1.82
DC	140.96±13.0	142.20±9.31	133.54±12.78	139.78±10.43	145.70±15.00	141.72±12.78
INS	144.38±9.06	183.00±40.02	194.38±39.29	184.20±40.63	197.58±37.56	171.50±40.41
GB	156.80±0.89	149.65±2.29	164.55±3.31	171.80±11.30	153.83±8.73	157.83±5.31
VA	157.13±5.54	155.45±9.16	158.32±5.27	158.47±13.17	170.78±8.10	173.43±15.51
MO	141.45±5.05	142.65±4.95	137.05±0.65	142.75±23.75	160.60±8.80	162.45±11.85
VA+MO	159.30±12.28	161.40±13.05	148.85±5.10	149.23±6.54	144.02±8.80	146.60±11.12

Values are Mean±SEM and n=3 determinations. *Significantly different from NC at (P<0.05). NC: Normal control; DC: diabetic control; GB: glibenclamide, MO: *Moringa oleifera*; VA: *Vernonia amygdalina*; INS: insulin.




Figure 1. Initial and final blood glucose concentration of the different experimental groups. Values are Mean±SEM. *Significantly different from NC at P<0.05. ^aP<0.05 vs. DC; ^bP<0.05 vs. GB; ^cP<0.05 vs. INS; ^aP<0.05 vs. MO. NC: Normal control; DC: diabetic control; GB: glibenclamide, MO: *Moringa oleifera*; VA: *Vernonia amygdalina*; INS: insulin.

STZ. This resulted in the destruction of the majority of the β -cells of the islets of Langerhans and pancreatic dysfunction. Secondly, diabetes induction caused hepatotoxicity and oxidative stress to the liver, which was confirmed by the presence of oxidative marker enzymes in the blood. Diabetes inflamed lipid components in the plasma and electrolytes in the kidney, resulting in dyslipidemia and electrolyte disruption. Finally, the mal-

functioning of the pancreas as a result of the diabetic condition led to an increase in blood glucose sugar and a general loss of weight in untreated diabetic animals.

The mechanism by which STZ induces diabetes is thought to be through its entry into the β -cells via a glucose transporter (GLUT2) where it causes alkylation of DNA molecule and its eventual damage. DNA damage in turn induces the activation of poly-ADP-ribosylation, a

process that is more important for the diabetogenicity of STZ than DNA damage itself. Poly-ADP-ribosylation leads to depletion of cellular nicotinamide adenine dinucleotide (NAD⁺) and adenosine triphosphate (ATP). Enhanced ATP dephosphorylation after STZ treatment supplies a substrate for xanthine oxidase resulting in the formation of superoxide radicals, hydrogen peroxide radicals and hydroxyl radicals *in vivo*. STZ also liberates toxic amounts of nitric oxide into the body, and this inhibits aconitase activity and participates in DNA damage. As a result of the STZ action, β -cells undergo destruction by necrosis (Szkudelski, 2001). In STZ induced diabetic rats, the elevation in fasting blood glucose along with decrease in liver glycogen levels may be due to lower levels of plasma insulin (Maiti et al., 2004).

V. amygdalina have been shown to lower blood sugar with attendant weight benefits (Igile et al., 1995), and several studies have shown the benefits of this plant in the management of endocrine related diseases such as diabetic conditions (Atangwho et al., 2009). Studies have also confirmed the ethno-pharmacological use of *M. oleifera* in the management of diabetes related illnesses.

However, no studies have been carried out involving the administration of the combined leaf extracts of these two plants that have shown so much promise in the alleviation of diabetic conditions in man. This study was carried out to compare the hepatoprotective effect, body weight management and blood glucose lowering efficacy of the combined extract of the two plants with the results of single plant extract administration.

The combined extract of the two plants effectively healed the liver and decreased the oxidative stress enzymes in the plasma. The combined extract caused weight gain in diabetic rats, increased albumin and protein levels in blood and significantly reversed diabetes in the rats by decreasing blood glucose sugar (Figure 1). These results are consistent with earlier results by Anwana and Garland (1991).

Both plant extracts when combined not only show their abilities in lowering the levels of oxidative stress enzymes (ALT, AST and ALP) in serum, but similar with the standard anti-diabetic drugs (glibenclamide and insulin). The observed significant increase in the activity of AST alone confirms it is a more reliable marker of liver integrity than AST.

Albumin and globulin are important in the transport of hormones synthesized in the liver and serve as indicators of the immune status especially in disease states. Hepatotoxicity and general oxidative stress caused by diabetic conditions, directly affect the integrity and functioning of these two biomolecules. The results in this study showed that, combined ethanolic leaf extract of both plants showed a greater ability in synthesizing albumin and globulin when compared with the standard anti-diabetic drugs. These findings are promising, because it gives hope for the better management of diabetes

mellitus over the conventional medications due to the fact that it is safe, cheap and readily available.

Diabetes mellitus has become a growing problem in the world today (Piyush et al., 2006). It is associated with genetic factors, environmental factors and general lifestyle. In most cases, it is said to have its origin from obesity, which directly predisposes the diabetic condition. At the present rate of its increase, it may turn out to be one of the world's most common diseases and biggest public health burdens, with an estimated minimum of half-a-billion cases over the next decade (Joseph and Jini, 2011; Diamond, 2003). Nigeria with an estimated population of nearly 200 million people and its pattern of diets and lifestyle is already an obese and diabetic society. This astronomical increase in the prevalence of diabetes has made diabetes a major public health challenge for Nigeria and many other countries. The Nigerian population benefits from the indigenous ethno-pharmacological flora in the management of diabetes and other metabolic diseases. The study showed that the combined administration of *V. amygdalina* and *M. oleifera* produced weight gain, hypoglycaemia and hepato-protection in experimentally induced type 1 diabetic albino Wistar rats. The findings in this study are similar to other studies of researchers, who had variously demonstrated that the extract from *V. amygdalina* possesses antidiabetic properties (Minari, 2012; Akah and Okafor, 1992a,b; Sabu and Kutan, 1982). *M. oleifera* have also been shown to possess glucose lowering effect in STZ-induced diabetic rats by possibly stimulating the B -cells of the islets of Langerhans or due to its insulin-like activity (Tende et al., 2011). *M. oleifera* and *V. amygdalina* leaves extract have also shown some protective effect on the liver from other studies (Buraimoh et al., 2010; Ojiako and Nwanjo, 2006). The aqueous leaf extract of *V. amygdalina* may have exhibited hepato-protective activity due to its antioxidant property and its flavonoid content (Igile et al., 1994), and also may be as a result of the sesquiterpene lactones and saponins constituents.

The administration of combined leaf extracts of both plants showed a potential effect which may be due to a synergy between the bioactive secondary compounds from these two plants. This agrees with another study which showed that there appears to be a complement of bioactive principles in the leaves of these plants, and this may account for their hypoglycemic action (Atangwho et al., 2009).

Conclusion

The combined herbal treatment has demonstrated liver protective effect against STZ-induced hepatotoxicity on serum levels of liver enzymes and total proteins, thus confirming their uses as hepatoprotective and anti-diabetic agents. This study showed that combined extract

of *M. oleifera* and *V. amygdalina* can protect against STZ-induced toxicities. The present findings provide scientific evidence to the ethnomedicinal use of *M. oleifera* and *V. amygdalina* in treating liver diseases. It is therefore concluded that 100 mg/kg body weight of combined extract of *M. oleifera* and *V. amygdalina* is nearly as potent as 1 unit of insulin in reversing oxidative stress and hyperglycemia in diabetic rats.

REFERENCES

- Akah PA, Okafor CI (1992a). Blood sugar lowering effect of *Vernonia amygdalina* (Del) in an experimental rabbit model. *Phytother. Res.* 6(3):171-173.
- Akah PA, Okafor CI (1992b). Hypoglycaemic effect of *Vernonia amygdalina* (Del) in experimental rabbits. *Plant Med. Res.* 1:6-10.
- Anwana AB, Garland HO (1991). Intracellular dehydration in the rat made diabetic with streptozotocin: Effects of infusion. *J. Endocrinol.* 128:333-337.
- Atangwho IJ, Ebong PE, Eyong EU, Williams IO, Eteng MU, Egbung GE (2009). Comparative chemical composition of leaves of some antidiabetic medicinal plants: *Azadirachta indica*, *Vernonia amygdalina* and *Gongronema latifolium*. *Afr. J. Biotechnol.* 8(18):4685-4689.
- Buraimoh AA, Bako IG, Ibrahim FB (2010). Hepatoprotective effect of ethanolic leave extract of *Moringa oleifera* on the histology of paracetamol induced liver damage in Wistar rats. *Int. J. Anim. Vet. Adv.* 3(1):10-13.
- Cockram CS, Woo J, Lau E, Chan JCN, Lau J, Swaminathan R, Daonnan SPB (1993). Prevalence of diabetes mellitus and impaired glucose tolerance among Hong Kong Chinese adults of working age. *Diab. Res. Clin. Pract.* 21:65-72.
- Diamond J (2003). "The double puzzle of diabetes". *Nature* 423:599-602.
- Gagliano N, Grizzi F, Annoni G (2007). Mechanism of aging and liver functions. *Dig. Dis. Sci.* 25:118-123.
- Igile GO, Wieslaw O, Marian J, Stanislaw B, Michael F, Adetunde F (1994). Flavonoids from *Vernonia amygdalina* and their antioxidant activities. *J. Agric. Food Chem.* 42:2445-2448.
- Igile GO, Wieslaw O, S Burda, M Jurzysa (1995). Nutritional assessment of *Vernonia amygdalina* leaves in growing mice. *J. Agric. Food Chem.* 43:2162-2166.
- Joseph B, Jini D (2011). An insight in hypoglycemic effect of traditional indian herbs used in the treatment of diabetes. *Res. J. Med. Plant* 5:352-376.
- Jung M, Park M, Lee HC, Kang Y, Kang ES, Kim SK (2006). Antidiabetic agent from medicinal plants. *Curr. Med. Chem.* 13(10):1203-1218.
- Kelly CM, Fantus IC (1995). Insulin binding in non-insulin dependent diabetes mellitus (NIDDM) is correlated with glycaemic control: Clinical evidence for abnormal receptor regulation in NIDDM. *Metabolism* 4:506-512.
- Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA, Uematsu S, Akira S, Hengartner H, Zinkernagel RM (2005). Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. *Nat. Med.* 11:138-145.
- Maton A, Jean H, McLaughlin CW, Warner MQ, Lattart D, Wright JD (1993). *Human Biology and Health*. Eaglewood Cliffs, New Jersey, Prentice Hall, USA.
- Maiti R, Jana D, Das UK, Ghosh D (2004). Antidiabetic effect of aqueous effect of seed of *Tamarindus indica* in streptozotocin-induced diabetic rats. *J. Ethnopharmacol.* 92:85-91.
- Minari JB (2012). Hepatoprotective effect of methanolic extract of *Vernonia amygdalina* leaf. *J. Nat. Prod.* 5(2012):188-192.
- Ojiako OA, Nwanjo HUI (2006). *Vernonia amygdalina* hepatotoxic or hepatoprotective? Response from biochemical and toxicity studies in rats. *Afr. J. Biotechnol.* 5(18):1648-1651.
- Piyush MP, Natvarlal MP, Ramesh KG (2006). Holistic classification of herbal antidiabetics: A review. *Pharma Times* 38(5):19-25.
- Sabu M, Kuttan R (1982). Antidiabetic activity of medicinal plants and its relationship with their antioxidant property. *J. Ethnopharmacol.* 81:155-160.
- Saxena A, Kishore VN (2004). Role of selected medicinal Indian plants in management of type 2 diabetes: A review. *J. Alternat. Complement. Med.* 10(2):369-378.
- Szkudelski T (2001). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. *Physiol. Res.* 50(6):537-546.
- Tende JA, Ezekiel I, Dikko AAU, Goji ADT (2011). Effect of ethanolic leaves extract of *Moringa oleifera* on blood glucose levels of streptozotocin-induced diabetics and normoglycemic Wistar rats. *Br. J. Pharm. Toxicol.* 2(1):1-4.
- Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R (2006). Intensive insulin therapy in the medical ICU. *N. Engl. J. Med.* 354(5):449-461.
- Wild S, Roglic G, Green A, Sicree A, King H (2004). "Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030". *Diabetes Care* 27(5):1047-1053.

Full Length Research Paper

Comparison between the clinical efficacy of linagliptin and sitagliptin

Naoto Kamatani^{1*}, Taiya Katoh¹, Yoshikuni Sawai¹, Hitoshi Kanayama¹, Naoyuki Katada¹ and Mitsuyasu Itoh²

¹Department of Internal Medicine, Toyota Kosei Hospital, JA Aichi Koseiren Toyota, Aichi, 470-0396, Japan.

²Department of Endocrinology, Metabolism and Internal Medicine, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan.

Accepted 28 August, 2013

After the introduction of dipeptidylpeptidase-4 (DPP-4) inhibitors into the treatment for diabetes, these drugs have been widely used because of their capability and safety. Therefore, the clinical efficacy of linagliptin to sitagliptin was compared. Patients with type 2 diabetes, in whom pharmacological treatment was recently started, were randomly assigned to two separate groups, namely sitagliptin (50 mg/day) group and linagliptin (5 mg/day) group. A total of 42 patients (21 patients in each group), who received a single dose of their respective pharmacological agents, were evaluated in this study. The study primarily focused on changes in HbA1c levels before and 24 weeks after drug administration and effects of these drugs on renal function, liver function, and fat. Significant improvement in HbA1c levels (%) was found in both linagliptin and sitagliptin groups. Significant improvements were observed in low density lipoprotein-cholesterol (LDL-C) levels in patients in the linagliptin group. Linagliptin offers a great potential in terms of improving effect on blood glucose and lipid profile. This study has demonstrated that linagliptin can be a valuable option in the treatment of patients with type 2 diabetes.

Key words: Linagliptin, dipeptidylpeptidase-4 (DPP-4) inhibitors, type 2 diabetes, glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C).

INTRODUCTION

Dipeptidylpeptidase-4 (DPP-4) inhibitors were recently introduced as new oral antidiabetic drugs and have quickly come into use in clinical practice. DPP-4 inhibitors are noteworthy pharmacological agents, with new components being consecutively developed. DPP-4 inhibitors result in an increase in blood concentrations of glucagon-like peptide-1 (GLP-1) by inhibiting the DPP-4 effects *in vivo*. They result in an increase in blood levels of insulin by promoting insulin secretion from pancreatic β cells. In patients with type 2 diabetes, if the glucagon concentration is decreased, DPP-4 inhibitors also inhibit the increase in

blood glucose levels (Drucker and Nauck, 2006). A number of DPP-4 inhibitors are currently being used in clinical practice. Among the DPP-4 inhibitors, linagliptin is excreted through biliary tract, and because of its characteristic route of excretion, it may potentially be useful for patients with type 2 diabetes who are at a high risk of reduced renal function (Heise et al., 2009). Therefore, this study compared the clinical efficacy of linagliptin to the first DPP-4 inhibitor, sitagliptin. A prospective comparative study was conducted on the clinical effects of linagliptin and sitagliptin.

Table 1. Patient characteristics at the beginning of the study.

Characteristic	Linagliptin group	Sitagliptin group
Age (years)	50.8 ± 14.9	51.4 ± 13.8
Gender (human: male/female)	12/9	7/14
HbA1c (%) (mmol/mol)	6.9 ± 0.8 (52 ± 9)	7.3 ± 0.9 (56 ± 10)
Fasting blood glucose level (mg/dl)	145.1 ± 50.6	146.8 ± 43.6
HDL-C (mg/dl)	55.5 ± 16.1	57.8 ± 12.9
LDL-C (mg/dl)	148.1 ± 48.5	128.7 ± 36.8
Creatinine (mg/dl)	0.65 ± 0.2	0.57 ± 0.1
eGFR	101.7 ± 47.1	102.6 ± 26.6
AST (IU/L)	29.8 ± 19.7	34.2 ± 16.3
ALT (IU/L)	42.8 ± 35.4	45.5 ± 29.5

Mean ± SD (except for gender).

MATERIALS AND METHODS

Patients with type 2 diabetes, in whom pharmacological treatment was recently initiated at our hospital, were randomly assigned to two separate groups, namely sitagliptin (50 mg/day) and linagliptin (5 mg/day) groups. A total of 42 patients (21 patients in each group), who received a single dose of their respective pharmacological agents, were evaluated in this study. The study primarily focused on changes in HbA1c (HbA1c was measured in National Glycohemoglobin Standardization Program (NGSP) values. It was measured in Toyota Kosei Hospital Japan with a measuring instrument of TohSoh Inc. The calculated regression equation is $NGSP = 0.09148 (IFCC) + 2.152$ (David, 2012), which is the levels before and 24 weeks after drug administration and the influence of drug administration on renal function, liver function, and fat. Patient characteristics in sitagliptin and linagliptin groups were as follows: age (mean ± standard deviation (SD)): 51.4 ± 13.8 and 50.8 ± 14.9; gender (male:female): 7 males:14 females and 12 males:9 females; baseline HbA1c: 7.3 ± 0.9 and 6.9 ± 0.8 (%); 56 ± 10 and 52 ± 9 (mmol/mol) and baseline fasting blood glucose levels (mg/dl): 146.8 ± 43.6 and 145.1 ± 50.6 (Table 1). For statistical evaluations, paired Student's t-test was used to evaluate the therapeutic efficacy of the drugs.

This study has been reviewed and approved by the ethical review committee of Toyota Kosei Hospital. And this trial was registered with UMIN (no. 000010998).

RESULTS

Significant improvement in HbA1c levels was found in both linagliptin and sitagliptin groups (Figure 1), namely in patients in the sitagliptin group, in whom HbA1c levels changed from 7.29 ± 0.9% (56 ± 10 mmol/mol) (before administration of sitagliptin) to 6.72 ± 0.8 (%) (50 ± 9 mmol/mol) (24 weeks after administration) and in patients in the linagliptin group, in whom levels changed from 6.94 ± 0.8% (52 ± 9 mmol/mol) (before administration of linagliptin) to 6.32 ± 0.5% (45 ± 6 mmol/mol) (24 weeks after administration). Renal function was evaluated on the basis of the eGFR (ml/min/1.73 m²) and blood creatinine levels (mg/dl). The eGFR (ml/min/1.73 m²) changed from 102.6 ± 26.6 to 99.0 ± 28.9 in patients in the sitagliptin group and from 101.7 ± 47.0 to 102.0 ± 43.8 in patients in

the linagliptin group. Blood creatinine levels (mg/dl) changed from 0.57 ± 0.1 to 0.60 ± 0.2 in patients in the sitagliptin group and from 0.65 ± 0.2 to 0.64 ± 0.2 in patients in the linagliptin group. No marked changes in renal function for eGFR and creatinine levels were found in patients in the two groups. Liver function was evaluated on the basis of aspartate transaminase (AST) and alanine aminotransferase (ALT) levels (IU/l). AST level (IU/l) ranged from 34.2 ± 16.3 to 26.5 ± 11.8 in patients in the sitagliptin group and from 29.8 ± 19.7 to 23.3 ± 9.8 in patients in the linagliptin group. Significant improvements were observed in AST and ALT levels in patients in the sitagliptin group; these levels also improved in patients in the linagliptin group. Fat was evaluated on the basis of the high density lipoprotein-cholesterol (HDL-C) (mg/dl) and low density lipoprotein-cholesterol (LDL-C) levels (mg/dl). HDL-C level (mg/dl) changed from 57.8 ± 12.9 to 59.0 ± 13.3 in patients in the sitagliptin group and from 55.5 ± 16.1 to 58.4 ± 14.9 in patients in the linagliptin group, whereas LDL-C level (mg/dl) changed from 128.7 ± 36.8 to 121.0 ± 25.4 in patients in the sitagliptin group and from 148.1 ± 48.5 to 106.2 ± 23.8 in patients in the linagliptin group, showing a significant improvement (Figure 2).

DISCUSSION

Results of a recent meta-analysis have shown that the effects of sitagliptin 100 mg and linagliptin 5 mg were comparable (Gross et al., 2013). In the present study, a comparison between the actual clinical use of linagliptin 5 mg and long-term use of sitagliptin 50 mg demonstrated that their effect on glycemic control was virtually the same. In addition, the tests conducted in our hospital on eGFR and creatinine suggested that there was a marginal effect on renal function. However, at the 72nd annual meeting of the American Diabetes Association (ADA) held in 2012, the administration of linagliptin was reported to result in an improvement in albuminuria (Groop et al., 2012), and more detailed studies are expected to be conducted in the




Figure 1. Study of changes in HbA1c levels, *P<0.05.




Figure 2. Study of the changes in LDL-C levels, *P<0.05.

future. Improvement in LDL-C level has been reported from experiments conducted on mice (Thomas et al., 2008). In addition, the presence of GLP-1 receptors on the surface of human hepatocytes was confirmed in 2010 (Gupta et al., 2010), and stimulation of either GLP-1 or GLP-1 receptor agonists promoted phosphorylation of PDK-1, PKC ζ , and AKT, which are important for transduction of signals from intracellular insulin receptors. Previous studies have suggested that signals from GLP-1 receptors may promote stimulation and activation of the insulin signaling pathway; this mediates an inhibitory effect on hepatic steatosis by exerting a direct action on

hepatocytes (Ono et al., 2011). Unlike any other DPP-4 inhibitor, linagliptin has a unique structure composed of a xanthine skeleton, and some compounds containing this xanthine skeleton have been found to possess an antioxidant effect, suggesting that linagliptin may also possess similar antioxidant properties (Kröller-Schön et al., 2012; Ishibashi et al., 2013). Thus, linagliptin may potentially have improving effects on fatty liver, thereby improving effects on fat. This study also suggested that serum levels of LDL-C were significantly improved in patients in the linagliptin group.

Further studies are required in a large number of patients.

Linagliptin, which is the first DPP-4 inhibitor that can be eliminated through biliary excretion, offers a great potential in terms of improving effect on blood glucose and lipid profile.

This study has demonstrated that the effect of newly developed DPP-4 inhibitor, linagliptin, was almost similar to that of other DPP-4 inhibitors, which have been used in clinical practice. In addition, because of its unique property of being eliminated through biliary excretion, it is believed to have marginal impact on renal or hepatic functions. In the future, linagliptin can be a valuable option in the treatment of patients with type 2 diabetes.

ACKNOWLEDGEMENT

The authors thank Ms. Y. Tokura for her technical help.

ABBREVIATIONS

DPP-4, Dipeptidylpeptidase-4; **GLP-1**, glucagon-like peptide-1; **HbA1c**, glycated hemoglobin; **eGFR**, estimated glomerular filtrating ratio; **AST**, aspartate aminotransferase; **ALT**, alanine aminotransferase; **HDL-C**, high-density lipoprotein cholesterol; **LDL-C**, low-density lipoprotein cholesterol.

REFERENCES

- David BS (2012). Measurement of hemoglobin A(1c): A new twist on the path to harmony. *Diabetes Care* 35(12):2674-2680.
- Drucker DJ, Nauck MA (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. *Lancet* 368(9548):1696-1705.
- Groop P, Cooper M, Perkovic V, Emser A, Von Eynatten M, Woerle H (2012). Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment for Diabetic Nephropathy. Poster No. 953-P. Presented at the American Diabetes Association® (ADA) 72nd Scientific Sessions. June 8-12, Philadelphia, PA.
- Gross JL, Rogers J, Polhamus D, Gillespie W, Friedrich C, Gong Y, Monz BU, Patel S, Staab A, Retlich S (2013). A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: An example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. *BMJ*. 3(3):e001844.
- Gupta NA, Mellis J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA (2010). Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. *Hepatology* 51(5):1584-1592.
- Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommehauser D, Dugi KA (2009). Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. *Diabetes Obes. Metab.* 11(8):786-794.
- Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi SI (2013). Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. *Cardiovasc. Diabetol.* 12(1):125.
- Kröller-Schön S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, Sudowe S, Scholz A, Daub S, Karbach S, Kossmann S, Gori T, Wenzel P, Schulz E, Grabbe S, Klein T, Münzel T, Daiber A (2012). Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. *Cardiovasc. Res.* 96(1):140-149.
- Ono M, Oe K, Saibara T (2011). Attenuation of fatty accumulation in hepatocyte by incretin--expectation of novel medicine for treatment of NASH. *Nihon Rinsho.* 69(5):853-858.
- Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M (2008). (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-Quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione(BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. *J. Pharmacol. Exp. Ther.* 325(1):175-182.

UPCOMING CONFERENCES

14th Annual Scottish Conference of the Diabetic Foot



20th World congress on Parkinson's Disease and Related Disorders, Geneva, Switzerland, 8 Dec 2013



Conferences and Advert

October 2013


7th World Congress on Diabetes & Obesity, Riga, Latvia, 24 Oct 2013

November 2013

4th International Diabetic Foot Conference

December 2013

20th World congress on Parkinson's Disease and Related Disorders, Geneva, Switzerland, 8 Dec 2013



Journal of Diabetes and Endocrinology

Related Journals Published by Academic Journals

- *African Journal of Pharmacy and Pharmacology*
- *Journal of Dentistry and Oral Hygiene*
- *International Journal of Nursing and Midwifery*
- *Clinical Reviews and Opinions*
- *Journal of AIDS and HIV Research*
- *International Journal of Nutrition and Metabolism*

academicJournals